Immunome, Inc.

Director / Senior Director, US Market Access

Immunome, Inc.  •  $237k - $321k/yr  •  Bothell, WA (Onsite)  •  16 days ago
Apply
AI can make mistakes so check important info. Chat history is never stored.
56
AI Success™

Job Description

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugate therapies. Our pipeline includes varegacestat, a late-clinical stage GSI; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recently received IND clearance. We are also advancing a broad portfolio of early stage ADCs pursuing undisclosed solid tumor targets.

Immunome is seeking an experienced and strategic Director / Senior Director, US Market Access to develop and execute the US market access strategy for our oncology portfolio. This role will lead payer and channel strategy for varegacestat from pre-launch through launch, overseeing payer marketing materials, pricing, value proposition development, and contracting, while also helping shape U.S. market access strategy for pipeline assets as they advance into late-stage development.

The successful candidate will bring deep expertise in the US payer landscape and specialty access pathways, along with a proven track record executing market access plans that maximize patient access. This role will partner closely with HEOR, Distribution/Trade, and field teams to deliver coverage, pull-through, and patient access solutions.

Responsibilities

Strategic Market Access Leadership

  • Develop the integrated US market access strategy for pipeline and launch products across commercial, Medicare, Medicaid, and institutional segments.
  • Lead access planning and launch readiness, including payer segmentation, access objectives, and pull-through tactics.
  • Track access KPIs (coverage, utilization management, time-to-therapy, net price) and drive actions to remove barriers.

Value Proposition, Evidence and Payer Marketing Materials

  • Partner with HEOR and Medical to define the value story, evidence plan, and payer value proposition.
  • Lead/co-lead development of payer-facing materials (AMCP dossier, value deck, formulary submission tools, reimbursement guides).
  • Support field execution through training, messaging, and tools for payer discussions and pull-through.

Pricing Strategy and Contracting

  • Develop US pricing strategy and gross-to-net assumptions; support pricing governance and scenario modeling.
  • Lead contracting strategy and execution with payers, PBMs, IDNs, and key customers; coordinate operational implementation with Legal/Compliance and Distribution/Trade.

Channel, Distribution and Patient Access Operations

  • Collaborate with Distribution/Trade and Patient Services to define and execute on channel and distribution strategy (e.g., specialty pharmacy, specialty distributor, wholesaler).
  • Support patient access services (benefit verification, prior authorization support, copay/PAP, hub operations) to reduce time-to-therapy.
  • Monitor payer policy and reimbursement changes; use analytics and field feedback to proactively address access issues.

Leadership and Collaboration

  • Serve as market access lead across cross-functional teams (HEOR, Medical, Commercial/Brand, Distribution/Trade, and field).
  • Provide clear access insights and recommendations to senior leaders, translating payer feedback into decisions.
  • Build relationships with payers and health systems; lead payer research/advisory boards and manage external partners as needed.

Qualifications

  • Bachelor's degree required; advanced degree (MBA, MPH, PharmD) preferred.
  • Director: 7+ years in US market access/pricing/contracting or ; Senior Director: typically 9+ years with leadership experience.
  • Demonstrated success developing and executing US market access strategies for specialty products; oncology preferred.
  • Experience developing payer marketing deliverables (AMCP dossier, payer value deck, value proposition) with HEOR/Medical.
  • Proven track record negotiating and implementing payer/customer contracts to maximize patient access.
  • Experience partnering with Distribution/Trade and patient services models (specialty pharmacy, buy-and-bill, hub, copay/PAP).
  • Strong influencing and communication skills; ability to thrive in a fast-paced biotech environment.

Knowledge and Skills

  • Deep understanding of US reimbursement across Commercial, Medicare (Part D/Part B), Medicaid, and institutional segments.
  • Strong knowledge of specialty access pathways, utilization management levers, and patient affordability; oncology experience strongly preferred.
  • Expertise in strategic pricing, contracting structures, gross-to-net drivers, and access analytics.
  • Ability to translate clinical and economic evidence into clear, compelling payer value narratives and materials.
  • Demonstrated success partnering with HEOR, Distribution/Trade, and field teams to drive execution and pull-through.
  • Excellent negotiation, presentation, and executive-level communication skills.
  • Analytical mindset and comfort using data to track access performance and inform decisions.
  • Strong project management skills and ability to manage vendors/consultants and multiple priorities.

Washington State Pay Range $236,650$320,791 USD

E/E/O

Immunome, Inc. is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.

E-Verify

Immunome, Inc. is a participant in E-Verify. Please review the following notices: E-Verify Participation Poster | Right to Work Poster (English) | Right to Work Poster (Spanish)

Immunome, Inc.

About Immunome, Inc.

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.

Industry
Biotech & Life Sciences
Company Size
51-200 employees
Headquarters
Bothell, Washington
Year Founded
Unknown
Social Media